Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.65 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741339 | 0.85 | SIRT6 (0.62) | HTR1ASIRT6LMNAPOLBMAPT | |
| SCHEMBL1045292 | 0.84 | SIRT6 (0.69) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL12431530 | 0.82 | MAPT (0.70) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL6945690 | 0.81 | SIRT6 (0.65) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL4628534 | 0.81 | SIRT6 (0.64) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL6151796 | 0.81 | SIRT6 (0.64) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL15599506 | 0.81 | POLB (0.64) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL2717022 | 0.81 | SIRT6 (0.64) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL4820552 | 0.81 | SIRT6 (0.64) | HTR1ASIRT6LMNAPOLBKMT2A | |
| SCHEMBL4248033 | 0.81 | SIRT6 (0.64) | HTR1ASIRT6LMNAPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977352-B2 | Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-07-12 | — | — | US | disclosed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| EP-2086540-B1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-01-19 | — | — | EP | disclosed |
| EP-2086540-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105242-A1 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases | COL2A1, MMP1, COL1A1 | HTR1A 3204/4885SIRT6 1080/4885LMNA 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.